Ignite Creation Date:
2024-05-05 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00165347
Status:
COMPLETED
Last Update Posted:
2007-12-21
First Post:
2005-09-09
Brief Title:
Protein Tyrosine Kinases PTK in Multiple Myeloma
Sponsor:
Dana-Farber Cancer Institute
Organization:
Dana-Farber Cancer Institute
Study Overview
Official Title:
Phase II Study of PTK787ZK222584 in Multiple Myeloma
Status:
COMPLETED
Status Verified Date:
2007-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether or not cancer cells in the body are affected by PTK and whether it affects the growth of these cells
Detailed Description:
Patients will take PTK orally once a day for the duration of their time on the study Each cycle of chemotherapy will last for 4 weeks
Measurement of vital signs will be done weekly during the first month of treatment
Physical exam vital signs blood work a quality of life assessment and x-ray or MRI wil be performed every 4 weeks
Patients will remain on the study until their disease fails to respond to treatment or there are intolerable side effects Typically treatment is performed for 12 weeks and up to one year in patients that are stable and responding
Measurement of vital signs will be done weekly during the first month of treatment
Physical exam vital signs blood work a quality of life assessment and x-ray or MRI wil be performed every 4 weeks
Patients will remain on the study until their disease fails to respond to treatment or there are intolerable side effects Typically treatment is performed for 12 weeks and up to one year in patients that are stable and responding
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None